Video Insights
Video Insights
Advertisement
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | March 23, 2023
Drs. Kambhampati and Thiruvengadam discuss their study investigating the cost effectiveness of pola-R-CHP in DLBCL.
Listen Now
Sandy Wong, MDMyeloma | March 22, 2023
Novel therapies and “game-changing drugs” have made a major impact on the treatment of myeloma, Dr. Wong said.
Sandy Wong, MDMyeloma | March 20, 2023
Sandy Wong, MD, explains how clinicians and researchers can help educate others about myeloma.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | March 9, 2023
Graham Collins, MD, discusses how to navigate the latest research in Hodgkin lymphoma.
Sagar Lonial, MD, FACPMyeloma | March 6, 2023
Sagar Lonial, MD, FACP, Editor-in-Chief of Blood Cancers Today, discusses Multiple Myeloma Awareness Month.
Cecilia BrownViewpoints | February 28, 2023
Dr. Pickl discusses potential future uses and implications of a novel biomarker to predict responses to CAR-T in DLBCL.
Advertisement
Chadi Nabhan, MD, MBA, FACPViewpoints | February 24, 2023
Dr. Nabhan discusses his new book, "Toxic Exposure: The True Story behind the Monsanto Trials and the Search for Justice."
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 23, 2023
Dr. Bishop discusses the matter with host Chadi Nabhan, MD, MBA, FACP, and speaks about why CAR-T doesn't always work.
Cecilia BrownVideo Insights | February 22, 2023
Winfried F. Pickl, MD, discusses a novel biomarker that can predict CAR-T responses in patients with DLBCL.
Leah SherwoodAcute Myeloid Leukemia | February 13, 2023
The optical genome mapping platform will have clinical implications for patients with acute myeloid leukemia and MDS.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 9, 2023
Dr. Sehn also explains why the TRIANGLE study is anticipated to change practices surrounding transplant in MCL.
Cecilia BrownVideo Insights | February 8, 2023
The research has implications for patients with hematologic malignancies who need to undergo allogeneic HSCT.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | January 26, 2023
Sanam Loghavi, MD, chats with The HemOnc Pulse host Chadi Nabhan, MD, MBA, FACP, about why 2022 was a major year for MDS.
Tycel Phillips, MDVideo Insights | January 25, 2023
Tycel Phillips, MD, discusses a study evaluating glofitamab in patients with relapsed/refractory mantle cell lymphoma.
Michael Dickinson, MBBS, DMedSc, FRACP, FRACPAVideo Insights | January 20, 2023
Michael Dickinson, MBBS, DMedSc, discusses trials in progress that are evaluating glofitamab with other agents for DLBCL.
Michael Dickinson, MBBS, DMedSc, FRACP, FRACPAVideo Insights | January 18, 2023
Michael Dickinson, MBBS, DMedSc, discusses a phase II trial of glofitamab, a bispecific antibody, in patients with DLBCL.
Blood Cancers Today Staff WritersVideo Insights | January 17, 2023
The panel discusses new targets for DLBCL and FL and shares what excites them about the future for these diseases.
Blood Cancers Today Staff WritersVideo Insights | January 13, 2023
The panel discusses regulatory hurdles and patient access considerations for non-Hodgkin lymphoma therapies.
Michael Dickinson, MBBS, DMedSc, FRACP, FRACPAVideo Insights | January 13, 2023
Michael Dickinson, MBBS, DMedSc, discusses updates on glofitamab that were presented during the 2022 ASH meeting.
Cecilia BrownViewpoints | January 13, 2023
Mark Lawler, PhD, discusses insights from European Groundshot Report on survival trends and the future of cancer care.
Advertisement
Advertisement
Editorial Board